| Market Cap | 7.78M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -4.23M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -37.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -74.00% |
| Dividend | N/A | Price/Book | 0.67 | EPS next 5Y | - | 52W High Chg | -94.00% |
| Recommedations | - | Quick Ratio | 0.36 | Shares Outstanding | 358.45M | 52W Low Chg | 37.00% |
| Insider Own | 1.58% | ROA | -14.75% | Shares Float | 411.61M | Beta | -0.19 |
| Inst Own | 0.01% | ROE | -39.01% | Shares Shorted/Prior | -/- | Price | 0.02 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 574,206 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 477,153 | Change | 0.00% |
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. The company is based in Toronto, Canada.